ECSP11011405A - Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r - Google Patents
Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1rInfo
- Publication number
- ECSP11011405A ECSP11011405A EC2011011405A ECSP11011405A ECSP11011405A EC SP11011405 A ECSP11011405 A EC SP11011405A EC 2011011405 A EC2011011405 A EC 2011011405A EC SP11011405 A ECSP11011405 A EC SP11011405A EC SP11011405 A ECSP11011405 A EC SP11011405A
- Authority
- EC
- Ecuador
- Prior art keywords
- igf
- combination therapy
- specific inhibitors
- therapy used
- agents specific
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe la combinación de un antagonista de IGF-1R tal como un anticuerpo humanizado y un fármaco anti-proliferativo. En una realización preferida, la presente invención describe la combinación de un anticuerpo frente a IGF-1R y un fármaco anti-proliferativo que pertenece a la clase de inhibidor de EGFR, que es preferiblemente erlotinib. La combinación de acuerdo con la presente invención es útil para el tratamiento de tumores, que incluyen tumores mediados o dependientes de IGF-1R y/o EGFR.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16976809P | 2009-04-16 | 2009-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011405A true ECSP11011405A (es) | 2011-11-30 |
Family
ID=42982796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011405A ECSP11011405A (es) | 2009-04-16 | 2011-10-17 | Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20120058112A1 (es) |
| EP (1) | EP2419135A4 (es) |
| JP (1) | JP2012524087A (es) |
| KR (1) | KR20110140126A (es) |
| CN (1) | CN102458466A (es) |
| AU (1) | AU2010236818B2 (es) |
| BR (1) | BRPI1015216A2 (es) |
| CA (1) | CA2757730A1 (es) |
| CL (1) | CL2011002569A1 (es) |
| CO (1) | CO6571849A2 (es) |
| EC (1) | ECSP11011405A (es) |
| IL (1) | IL215363A0 (es) |
| MX (1) | MX2011010911A (es) |
| NZ (1) | NZ595755A (es) |
| RU (1) | RU2011146339A (es) |
| SG (1) | SG175208A1 (es) |
| WO (1) | WO2010120592A1 (es) |
| ZA (1) | ZA201107204B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103396488A (zh) | 2008-12-12 | 2013-11-20 | 贝林格尔.英格海姆国际有限公司 | 抗igf抗体 |
| US8470297B1 (en) * | 2009-09-10 | 2013-06-25 | Merck Sharp & Dohme Corp. | FDG-pet evaluation of Ewing's sarcoma sensitivity |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| GB201409488D0 (en) * | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CN105998033B (zh) * | 2016-07-05 | 2018-11-27 | 福州大学 | 一种含有厄洛替尼和熊果酸的药物组合物及其在制备抗肿瘤药物中的应用 |
| CN105963305B (zh) * | 2016-07-05 | 2018-08-17 | 福州大学 | 一种含酪氨酸激酶抑制剂的药物组合物及其在制备抗肿瘤转移药物中的应用 |
| WO2023081698A1 (en) * | 2021-11-02 | 2023-05-11 | Fusion Pharmaceuticals Inc. | Methods of treating cancer |
| WO2023235822A1 (en) * | 2022-06-03 | 2023-12-07 | Foundation Medicine, Inc. | Igf1r activation mutations and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101222926B (zh) * | 2005-04-15 | 2013-07-17 | 默沙东公司 | 用于治疗或预防癌症的方法和组合物 |
| US20090203718A1 (en) * | 2006-04-13 | 2009-08-13 | Smithkline Beecham (Cork) Ltd. | Cancer treatment method |
| EP2236139A1 (en) * | 2009-03-31 | 2010-10-06 | F. Hoffmann-La Roche AG | Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor |
-
2010
- 2010-04-06 RU RU2011146339/15A patent/RU2011146339A/ru not_active Application Discontinuation
- 2010-04-06 MX MX2011010911A patent/MX2011010911A/es unknown
- 2010-04-06 NZ NZ595755A patent/NZ595755A/xx not_active IP Right Cessation
- 2010-04-06 JP JP2012506067A patent/JP2012524087A/ja active Pending
- 2010-04-06 KR KR1020117024147A patent/KR20110140126A/ko not_active Application Discontinuation
- 2010-04-06 US US13/264,595 patent/US20120058112A1/en not_active Abandoned
- 2010-04-06 WO PCT/US2010/030022 patent/WO2010120592A1/en active Application Filing
- 2010-04-06 CA CA2757730A patent/CA2757730A1/en not_active Abandoned
- 2010-04-06 SG SG2011074721A patent/SG175208A1/en unknown
- 2010-04-06 CN CN2010800269747A patent/CN102458466A/zh active Pending
- 2010-04-06 BR BRPI1015216A patent/BRPI1015216A2/pt not_active IP Right Cessation
- 2010-04-06 EP EP10764915A patent/EP2419135A4/en not_active Withdrawn
- 2010-04-06 AU AU2010236818A patent/AU2010236818B2/en not_active Ceased
-
2011
- 2011-09-25 IL IL215363A patent/IL215363A0/en unknown
- 2011-10-03 ZA ZA2011/07204A patent/ZA201107204B/en unknown
- 2011-10-14 CL CL2011002569A patent/CL2011002569A1/es unknown
- 2011-10-17 EC EC2011011405A patent/ECSP11011405A/es unknown
- 2011-11-11 CO CO11154175A patent/CO6571849A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1015216A2 (pt) | 2016-04-12 |
| CL2011002569A1 (es) | 2012-04-09 |
| EP2419135A1 (en) | 2012-02-22 |
| MX2011010911A (es) | 2011-11-02 |
| AU2010236818B2 (en) | 2014-03-13 |
| RU2011146339A (ru) | 2013-05-27 |
| SG175208A1 (en) | 2011-11-28 |
| EP2419135A4 (en) | 2012-11-28 |
| CO6571849A2 (es) | 2012-11-30 |
| IL215363A0 (en) | 2011-12-29 |
| NZ595755A (en) | 2013-07-26 |
| KR20110140126A (ko) | 2011-12-30 |
| JP2012524087A (ja) | 2012-10-11 |
| US20120058112A1 (en) | 2012-03-08 |
| CA2757730A1 (en) | 2010-10-21 |
| CN102458466A (zh) | 2012-05-16 |
| ZA201107204B (en) | 2015-07-29 |
| AU2010236818A1 (en) | 2011-11-03 |
| WO2010120592A1 (en) | 2010-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011405A (es) | Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r | |
| CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
| CL2018000223A1 (es) | Combinación de antagonista de pd-1 con un inhibidor de egfr | |
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| CL2017000285A1 (es) | Terapia combinada para el tratamiento de un paramixovirus | |
| ECSP14013223A (es) | Métodos para tratar el cáncer por el uso de antagonistas de unión al eje pd-1 e inhibidores de mek | |
| CL2015002369A1 (es) | Uso de linagliptina en terapia antidiabética cardio y renoprotectora | |
| UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
| UY33498A (es) | Combinaciones de inhibidores de quinasas para el tratamiento de cancer | |
| EA201892625A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| EA202092456A2 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| GT201300320A (es) | Terapia de combinación que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cáncer. | |
| PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
| ECSP13012394A (es) | Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa | |
| CR20120638A (es) | Métodos de terapia combinada para tratar enfermedades proliferativas | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| CY1120751T1 (el) | Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων | |
| MX2014011500A (es) | Diagnosticos y tratamientos relacionados a inhibidores her3. | |
| CL2016000379A1 (es) | Composiciones y métodos terapéuticos para reducción acelerada de plagas | |
| CL2015003343A1 (es) | Composición farmacéutica que comprende un agente terapéutico modificado en base a hemoglobina, para el tratamiento para tratar el cáncer, e imágenes de diagnóstico. | |
| CY1120877T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης | |
| UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
| BR112014012495A2 (pt) | método in vitro, kit, inibidor de egfr e método de tratamento de pacientes afetados com câncer |